Fitch Ratings has affirmed the long-term ratings of McKesson Corp.
(NYSE: MCK), including the Issuer Default Rating (IDR) at 'BBB+'. The
Rating Outlook is revised to Stable from Negative.
A full list of rating actions, which apply to approximately $10.6
billion of debt at Sept. 30, 2014, follows at the end of this release.
KEY RATING DRIVERS
-- Fitch forecasts debt leverage to be above 2x at fiscal year-end 2015,
slightly above the target for the 'BBB+' ratings. But debt repayment
plans and solid EBITDA growth in fiscal 2016 should drive debt-to-EBITDA
of 1.7x or lower by the end of fiscal 2016.
-- The credit profiles of MCK and its peers benefit from stable
operating profiles and consistent cash generation. Steady pharmaceutical
demand and an oligopolistic drug distribution industry in the U.S. and,
for the most part in Western Europe, support strong ratings despite slim
margins.
-- Fitch generally sees the drug channel outside the U.S. as less stable
and higher risk, especially given the diversity of regulatory and
reimbursement systems. But inorganic growth opportunities are more
prevalent in markets outside the U.S., so McKesson's presence there is
important for long-term growth prospects.
-- Robust cash flows and solid capital market access contribute to a
strong liquidity profile and should enable MCK to de-lever in the
intermediate term. Cash flows are enhanced with the addition of Celesio
and expanded distribution agreements with Rite Aid Corp. and Omnicare
Inc. as the benefits of increased scale, especially in generic drug
purchasing, are realized over the next several years.
-- Global drug channel participants, including pharmaceutical
wholesalers, have benefited much from the unprecedented
branded-to-generic wave in 2011-2014. Growth of specialty drugs should
also provide profitability support beyond the generic wave, though the
most expensive therapies will be largely dilutive to margins. Pricing
pressure, especially in Europe, could offset some growth.
-- MCK holds top U.S. market positions in specialty drug distribution,
medical-surgical distribution, and healthcare IT, as well as drug
distribution in Canada. These businesses will support intermediate-term
growth and profitability and, in addition to measured expansion in other
non-U.S. markets, are likely to represent areas in which MCK will pursue
future growth opportunities over the ratings horizon.
RATING SENSITIVITIES
The 'BBB+' IDR incorporates the expectation that the firm will direct
cash flows to debt repayment such that debt-to-EBITDA of around 2x or
below is achieved by the end of fiscal 2016 (March 2016). Continued
strong and steady cash flows, accompanied by expected margin expansion
driven by the generally favorable industry tailwinds (i.e. generic
conversions, growth in specialty pharma) and improving purchasing scale
are also expected at the current ratings.
Ratings flexibility will be limited during this time of integration and
de-leveraging. A downgrade to 'BBB' could be driven by material
debt-funded acquisitions or the resumption of large-scale share
repurchases over the next couple of years, resulting in debt leverage
sustained at or above 2x. Fitch believes liquidity is adequate for
McKesson to purchase the remaining 24% of Celesio it does not own, if it
so chooses, at the current 'BBB+' ratings.
A positive rating action is not anticipated in the near term. An upgrade
to 'A-' will require a commitment to sustaining debt-to-EBITDA around
1.4x or below. Depending on management's capital deployment strategy,
this target is probably achievable in the years that follow the
currently contemplated de-leveraging horizon (e.g. fiscal 2017-2018).
FOCUS ON DEBT REPAYMENT IN FISCAL 2015-2017
Fitch expects MCK to limit share repurchase activity as it repays
virtually all debt maturities during fiscal 2015-2017, totaling up to
$3.8 billion (including the Celesio bonds due April 2017). Repaying this
full amount would likely drive McKesson's debt leverage back into a
range indicating positive rating momentum toward 'A-'. Fitch expects
cash generation and current liquidity will be more than ample to
accommodate such repayment.
However, a return to regular share repurchases and/or the refinancing of
debt post-2016 will likely be amenable at current ratings. The firm's
commitment to maintaining leverage at or below 1.4x such that an 'A-'
rating is attainable is at this time unknown.
INCREASING GENERICS SCALE, PROFITS FROM EXPANDED DISTRIBUTION AGREEMENTS
With the addition of the generic volumes from Rite Aid and Omnicare,
Fitch views McKesson as very strongly positioned among drug channel
participants to drive cost savings related to generic drug procurement.
The addition of Rite Aid and Omnicare generic drug volumes to McKesson's
purchasing arm should enhance the $275 million to $325 million synergy
number outlined publicly by management that refers to better generic
drug pricing available from the acquisition of Celesio. Incremental
product cost savings could drive material margin expansion and cash
generation over the next few years, particularly if additional large
customers that currently source and distribute the majority of their own
generic drug volumes.
These agreements have furthermore strengthened McKesson's leadership
position in North American drug distribution. Fitch forecasts revenues
for the North America pharmaceutical distribution business of $140
billion in fiscal 2015, rising to nearly $150 billion in 2016. Strong
growth is driven by a favorable drug pricing environment and improved
penetration with key customers. Growing generic drug volumes impacts
profitability more keenly than the top-line, however, and also
contributes to McKesson's ability to garner lower net product
acquisition costs going forward.
COST TO ACQUIRE REMAINING 24% OF CELESIO
The driver of the Negative Rating Outlook assigned in February 2014 was
the risk that McKesson would require additional debt funding to acquire
the remaining 25% of Celesio stock it did not acquire from Franz Haniel
& Cie GmbH (Haniel) and Elliott Fund Management (Elliott). At the time,
Fitch estimated the cost of this transaction at approximately $1.7
billion and were not sure when this cost may come to bear.
Pursuant to a subsequent tender offer early in 2014, McKesson reports
that it currently owns approximately 76% of the outstanding stock of
Celesio AG. Although not a 100% owner, McKesson achieved operational
control of Celesio under German law in December 2014. Acquiring the
remaining 24% does not impact McKesson's ability to direct the
operations and, more importantly, the cash flows of Celesio. The firm
has combined purchasing functions and begun to drive the targeted $275
million to $325 million of synergies over the next few years. Therefore,
it is not imperative that McKesson act quickly to purchase the Celesio
stock it does not currently own. Fitch does note, however, that
non-controlling owners have the right to put their Celesio stock to
McKesson at EUR22.99.
Although this risk remains, it is mitigated by McKesson's re-built
liquidity position, including $1.7 billion of U.S. cash and $2.1 billion
of cash held overseas at Sept. 30, 2014. Furthermore, the weakening Euro
and relatively stable stock price of Celesio has reduced Fitch's
estimated cost for McKesson to acquire the remaining portion of Celesio
stock to $1.3 billion. Celesio's stock has not traded below the EUR22.99
put option price since MCK announced its new deals with Haniel and
Elliot in January 2014.
STRONG MARGIN EXPANSION DRIVEN BY GENERIC WAVE, PRICING PRESSURE POSSIBLE
MCK and its peers continue to benefit from the unprecedented wave of
branded drug patent expirations in calendar 2011-2014. Most drug channel
participants, including distributors, earn higher margins - though less
revenues - on the sale of lower-cost generic drugs. Fitch believes much
of the margin expansion MCK and its peers have achieved from generic
conversions in recent years is durable, as generic penetration in the
U.S. is likely to remain above 80% (based on volumes) for many years to
come. Generic utilization is expected to improve in most non-U.S.
markets over the longer term.
Increasing pricing pressure within the drug channel is possible,
however, over the next couple of years. Especially in light of
legislated healthcare reform, it is possible that third-party payers
will begin focus more intently on profits associated with specialty and,
to a lesser extent, generic drugs. Drug distributors, while not immune,
are well-insulated from these types of pressures. Furthermore,
distributors' and pharmacies improving purchasing position with generic
drugmakers should help to strengthen their position as market-makers,
thereby supporting margins for the foreseeable future.
ROBUST CASH FLOWS AND SOLID LIQUIDITY; BUT UNKNOWN CAPITAL DEPLOYMENT
POST-2017
MCK's stable margins and good asset management contribute to stable and
strong cash generation measures. Funds from operations (FFO) for the
latest 12 month (LTM) period ended Sept. 30, 2014 was a robust $3.16
billion. Free cash flow (FCF; cash from operations less dividends and
capital expenditures) for the same period was $1.77 billion. Fitch
forecasts FFO and FCF of $2.8 billion and $2.7 billion in 2015,
respectively, and $3.3 billion and $3.1 billion in 2016, respectively.
Possible upside could come from more rapid pacing of purchasing synergy
capture from the addition of Celesio, Rite Aid, and Omnicare volumes.
Cash generation is expected to outpace debt maturities, and Fitch
expects all debt maturities in fiscal 2016 and 2017 to be repaid.
Long-term debt maturities are estimated as follows: $1.5 billion in
2016; $1.7 billion in 2017; $1.2 billion in 2018, and $5.4 billion
thereafter.
The company maintains a strong liquidity profile. At Sept. 30, 2014, MCK
had $3.8 billion of cash on hand ($2.1 billion OUS), as well as full
availability of its $1.3 billion revolver due September 2016 and its
$1.35 billion accounts receivable facility. Appropriate availability
under Celesio facilities is also maintained.
SOLID PRESENCE IN SPECIALTY, MED-SURG, AND HIT
Traditional drug distribution in the U.S. is an industry mostly
consolidated and characterized by steady growth in the low-single
digits. This activity accounts for roughly 80% of MCK's overall
revenues. The remaining 20% comes from the company's leading market
positions in the distribution of specialty pharmaceuticals and of
med-surg supplies, and in healthcare information technology (HIT). MCK
is one of only a handful of companies with a significant share of these
relatively fragmented markets.
As a result, Fitch believes MCK is uniquely positioned to benefit from
growth opportunities related to its ancillary businesses as those
markets grow and consolidate over time. To that end, Fitch expects MCK
to continue consummating small, tuck-in acquisitions in especially the
med-surg and HIT spaces. In general, the company approaches M&A
opportunistically and responsibly.
Fitch has affirmed the ratings of MCK as follows:
-- Long-term IDR at 'BBB+';
-- Senior unsecured bank facility at 'BBB+';
-- Senior unsecured notes at 'BBB+';
-- Short-term IDR at 'F2';
-- Commercial paper at 'F2'.
The Rating Outlook is revised to Stable from Negative.
Additional information is available at 'www.fitchratings.com'.
Applicable Criteria and Related Research:
--'Corporate Rating Methodology: Including Short-Term Ratings and Parent
and Subsidiary Linkage' (May 28, 2014);
--'Trekking the Path to Biosimilars - The Destination' (Oct. 4, 2013);
--'Trekking the Path to Biosimilars - Forging Ahead' (Aug. 5, 2013);
--'Vital Signs - Currents in the Drug Channel' (Podcast) (April 25,
2013);
--'Navigating the Drug Channel - Drug Distributors: A Deeper Dive'
(April 24, 2013).
Applicable Criteria and Related Research:
Corporate Rating Methodology - Including Short-Term Ratings and Parent
and Subsidiary Linkage
http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=749393
Trekking the Path to Biosimilars -- The Destination
http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=719802
Trekking the Path to Biosimilars -- Forging Ahead
http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=714715
Vital Signs -- Currents in the Drug Channel
http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=707243
Navigating the Drug Channel -- Drug Distributors: A Deeper Dive
http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=706690
Additional Disclosure
Solicitation Status
http://www.fitchratings.com/gws/en/disclosure/solicitation?pr_id=978667
ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND
DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING
THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS.
IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE
AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'.
PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS
SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS
OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES
AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF
THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE
RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR
RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY
CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH
WEBSITE.
Copyright Business Wire 2015